ALNY

Alnylam Pharmaceuticals, Inc. (ALNY)

Last Price$250.6(0.2%)

Market Cap$32.2B

LTM Net Debt to Free Cash Flow

32.8x

5Y avg

(0.4x)

Biotechnology industry median

1.0x

Stock quality & Intrinsic value

5/10

(0.6%) overvalued

is (61.9%) overvalued

undervalued stocks

Start beating the S&P 500

Alnylam Pharmaceuticals, Inc. Net Debt to Free Cash Flow

Annual

Quarterly

LTM

Industry median

Company stand-alone

ALNY

Healthcare

Crunching data... Almost there!

	Dec'04	Dec'05	Dec'06	Dec'07	Dec'08	Dec'09	Dec'10	Dec'11	Dec'12	Dec'13	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23
Net Debt to Free Cash Flow	1.4x	3.9x	7.0x	(2.4x)	(7.9x)	3.7x	2.6x	1.7x	1.8x	4.8x	5.6x	6.6x	2.1x	3.4x	1.5x	2.3x	2.0x	0.3x	(0.7x)	5.8x

ALNY

Key metrics and insights to make informed decisions.

View full analysis

Overvalued or undervalued?

Check the intrinsic value for ALNY and see if it's the right time to invest.

Alnylam Pharmaceuticals, Inc. (ALNY) Net Debt to Free Cash Flow comparison analysis

Crunching data... Almost there!

ALNY key stats

USD

Millions

Billions

Annual

Quarterly

Trailing

Key stats

Income statement

Balance sheet

Cash Flow Statement

Valuation

Ratios

Per share

Per employee

Dividends & Yields

Crunching data... Almost there!

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%

S&P Outperformance 19.1%

Next 3M Predicted Return 20.3%

Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%

S&P Outperformance 22.3%

Next 3M Predicted Return 26.8%

Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.

3M Return 28.4%

S&P Outperformance 15.4%

Next 3M Predicted Return 16.9%

FAQ

1) What is Alnylam Pharmaceuticals, Inc.'s Net Debt to Free Cash Flow?

As of today, Microsoft Corp's last 12-month Net Debt to Free Cash Flow is 32.8x, based on the financial report for Dec 31, 2024 (Q4 2024). The average annual Net Debt to Free Cash Flow for Alnylam Pharmaceuticals, Inc. have been (1.4x) over the past three years, and (0.4x) over the past five years.

2) Is Alnylam Pharmaceuticals, Inc.'s Net Debt to Free Cash Flow Good?

As of today, Alnylam Pharmaceuticals, Inc.'s Net Debt to Free Cash Flow is 32.8x, which is higher than industry median of 1.0x. It indicates that Alnylam Pharmaceuticals, Inc.'s Net Debt to Free Cash Flow is Bad.

3) How does Alnylam Pharmaceuticals, Inc.'s Net Debt to Free Cash Flow compare to its peers?

As of today, Alnylam Pharmaceuticals, Inc.'s Net Debt to Free Cash Flow is 32.8x, which is higher than peer median of (0.2x). The list of peers includes VRTX, SMMT, BGNE, NVO, RPRX, UTHR, REGN, INCY, BNTX, ARGX.